Prevalence of depressive symptoms and predictors of treatment among U.S. adults from 2005 to 2010

General Hospital Psychiatry

Volumn 36, Issue 3, 2014, Pages 330-336

  Wittayanukorn, Saranrat ^a   Qian, Jingjing ^a   Hansen, Richard A ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

Depression; Depressive symptoms; Prevalence; Treatment

Indexed keywords

MONOAMINE OXIDASE INHIBITOR; PHENYLPIPERAZINE; PIPERAZINE DERIVATIVE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TETRACYCLIC ANTIDEPRESSANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTHRITIS; ARTICLE; CAUCASIAN; COMORBIDITY; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEALTH DISPARITY; HEALTH INSURANCE; HEALTH SURVEY; HISPANIC; HOSPITALIZATION; HUMAN; HYPERTENSION; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY; PATIENT HEALTH QUESTIONNAIRE; POVERTY; PREVALENCE; QUESTIONNAIRE; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; UNITED STATES; ADOLESCENT; DEPRESSIVE DISORDER; MENTAL HEALTH SERVICE; MIDDLE AGED; NUTRITION; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; TRENDS; UTILIZATION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DEPRESSION; DEPRESSIVE DISORDER; HUMANS; MALE; MENTAL HEALTH SERVICES; MIDDLE AGED; NUTRITION SURVEYS; PREVALENCE; SEVERITY OF ILLNESS INDEX; UNITED STATES; YOUNG ADULT;

EID: 84898849702     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2013.12.009     Document Type: Article

References (57)

1. World Health Organization. Depression Fact Sheet no. 369. World Health Organization 2012.
2. Shim R.S., Baltrus P., Ye J., Rust G. Prevalence, treatment, and control of depressive symptoms in the United States: results from the National Health and Nutrition Examination Survey (NHANES), 2005-2008. J Am Board Fam Med: JABFM 2011, 24:33-38.
3. Stewart W.F., Ricci J.A., Chee E., Hahn S.R., Morganstein D. Cost of lost productive work time among US workers with depression. JAMA: the journal of the American Medical Association 2003, 289:3135-3144.
4. Egede L.E., Zheng D., Simpson K. Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. Diabetes care 2002, 25:464-470.
5. Soni A. Statistical Brief #377. Trends in use and expenditures for depression among US adults age 18 and older, civilian noninstitutionalized population, 1999 and 2009 2012, Agency for Healthcare Research and Quality, Rockville, MD.
6. Birnbaum H.G., Kessler R.C., Kelley D., et al. Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance. Depress Anxiety 2010, 27:78-89.
7. Pratt L.A., Brody J.D. NCHS Data Brief: Depression in the United States Household Population, 2005-2006 2008.
8. Lepine J.P., Briley M. The increasing burden of depression. Neuropsychiatric Dis Treat 2011, 7:3-7.
9. Onitilo A.A., Nietert P.J., Egede L.E. Effect of depression on all-cause mortality in adults with cancer and differential effects by cancer site. Gen Hosp Psychiatry 2006, 28:396-402.
10. Qian J., Simoni-Wastila L., Langenberg P., et al. Effects of depression diagnosis and antidepressant treatment on mortality in Medicare beneficiaries with chronic obstructive pulmonary disease. J Am Geriatr Soc 2013, 61:754-761.
11. Gump B.B., Matthews K.A., Eberly L.E., Chang Y.F. Depressive symptoms and mortality in men: results from the Multiple Risk Factor Intervention Trial. Stroke 2005, 36:98-102.
12. Shekelle R.B., Raynor W.J., Ostfeld A.M., et al. Psychological depression and 17-year risk of death from cancer. Psychosom Med 1981, 43:117-125.
13. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 2010.
14. Cuijpers P., van Straten A., Schuurmans J., et al. Psychotherapy for chronic major depression and dysthymia: a meta-analysis. Clin Psychol Rev 2010, 30:51-62.
15. Cuijpers P., van Straten A., van Oppen P., Andersson G. Are psychological and pharmacologic interventions equally effective in the treatment of adult depressive disorders? A meta-analysis of comparative studies. J Clin Psychiatry 2008, 69:1675-1685. quiz 1839-41.
16. Fournier J.C., DeRubeis R.J., Hollon S.D., et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010, 303:47-53.
17. Gartlehner G., Gaynes B.N., Hansen R.A., et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 2008, 149:734-750.
18. National Collaborating Centre for Mental Health (UK). Depression: The Treatment and Management of Depression in Adults (Updated Edition) NICE Clinical Guidelines, No 90 Leicester (UK): British Psychological Society, 2010.
19. Khan A., Faucett J., Lichtenberg P., Kirsch I., Brown W.A. A systematic review of comparative efficacy of treatments and controls for depression. PloS one 2012, 7:e41778.
20. Pratt L.A., Brody D.J., Gu Q. NCHS Data Brief: Antidepressant use in persons aged 12 and over: United States, 2005-2008 2011.
21. Crystal S., Sambamoorthi U., Walkup J.T., Akincigil A. Diagnosis and treatment of depression in the elderly medicare population: predictors, disparities, and trends. J Am Geriatr Soc 2003, 51:1718-1728.
22. Goldman L.S., Nielsen N.H., Champion H.C. Awareness, diagnosis, and treatment of depression. J Gen Intern Med 1999, 14:569-580.
23. Nutting P.A., Rost K., Dickinson M., et al. Barriers to initiating depression treatment in primary care practice. J Gen Intern Med 2002, 17:103-111.
24. U.S. Department of Health and Human Services. Office of Disease Prevention and Health Promotion. Healthy People 2020 summary of objectives: Mental health and mental disorders.
25. Baselga J., Perez E.A., Pienkowski T., Bell R. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 2006, 11(Suppl. 1):4-12.
26. Kroenke K., Spitzer R.L., Williams J.B. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001, 16:606-613.
27. Spitzer R.L., Kroenke K., Williams J.B. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999, 282:1737-1744.
28. Spitzer R.L., Williams J.B., Kroenke K., Hornyak R., McMurray J. Validity and utility of the PRIME-MD patient health questionnaire in assessment of 3000 obstetric-gynecologic patients: the PRIME-MD Patient Health Questionnaire Obstetrics-Gynecology Study. Am J Obstet Gynecol 2000, 183:759-769.
29. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington, DC., 2000.
30. Kroenke K., Spitzer R.L. A new depression diagnostic and severity measure. Psychiatr Annals 2002, 32:509-515.
31. Multum Lexicon Database. Multum Lexicon Database. Cerner Multum, Inc.
32. Schnell K., Weiss C.O., Lee T., et al. The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999-2008. BMC Pulm Med 2012, 12:26.
33. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. The American journal of clinical nutrition 1998;68:899-917.
34. U.S. Department of Health & Human Services. Health and Human Services Poverty (HHS) Guidelines. Washington, DC.
35. Marcus S.C., Olfson M. National trends in the treatment for depression from 1998 to 2007. Arch Gen Psychiatry 2010, 67:1265-1273.
36. Compton W.M., Conway K.P., Stinson F.S., Grant B.F. Changes in the prevalence of major depression and comorbid substance use disorders in the United States between 1991-1992 and 2001-2002. Am J Psychiatry 2006, 163:2141-2147.
37. Kwon A., Bungay K.M., Pei Y., et al. Antidepressant use: concordance between self-report and claims records. Medical Care 2003, 41:368-374.
38. Noyes K., Liu H., Lyness J.M., Friedman B. Medicare beneficiaries with depression: comparing diagnoses in claims data with the results of screening. Psychiatr Serv 2011, 62:1159-1166.
39. Simpson S.M., Krishnan L.L., Kunik M.E., Ruiz P. Racial disparities in diagnosis and treatment of depression: a literature review. Psychiatr Q 2007, 78:3-14.
40. Alegria M., Chatterji P., Wells K., et al. Disparity in depression treatment among racial and ethnic minority populations in the United States. Psychiatr Serv 2008, 59:1264-1272.
41. Akincigil A., Olfson M., Siegel M., et al. Racial and ethnic disparities in depression care in community-dwelling elderly in the United States. American journal of public health 2012, 102:319-328.
42. Olfson M., Liu S.M., Grant B.F., Blanco C. Influence of comorbid mental disorders on time to seeking treatment for major depressive disorder. Med Care 2012, 50:227-232.
43. Huang C.Q., Dong B.R., Lu Z.C., Yue J.R., Liu Q.X. Chronic diseases and risk for depression in old age: a meta-analysis of published literature. Ageing Res Rev 2010, 9:131-141.
44. Katon W.J. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry 2003, 54:216-226.
45. Polsky D., Doshi J.A., Marcus S., et al. Long-term risk for depressive symptoms after a medical diagnosis. Arch Intern Med 2005, 165:1260-1266.
46. Ali S., Stone M.A., Peters J.L., Davies M.J., Khunti K. The prevalence of co-morbid depression in adults with type 2 diabetes: a systematic review and meta-analysis. Diabet Med 2006, 23:1165-1173.
47. Zhang M.W., Ho R.C., Cheung M.W., Fu E., Mak A. Prevalence of depressive symptoms in patients with chronic obstructive pulmonary disease: a systematic review, meta-analysis and meta-regression. Gen Hosp Psychiatry 2011, 33:217-223.
48. Cohen H.W., Gibson G., Alderman M.H. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med 2000, 108:2-8.
49. Licht C.M., de Geus E.J., van Dyck R., Penninx B.W. Longitudinal evidence for unfavorable effects of antidepressants on heart rate variability. Biol Psychiatry 2010, 68:861-868.
50. Spina E., Santoro V., D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 2008, 30:1206-1227.
51. Edwards W.S., Winn D.M., Kurlantzick V., et al. Evaluation of National Health Interview Survey Diagnostic Reporting. National Center for Health Statistics. Vital Health Stat 2 1990, 1-116.
52. Barr R.G., Herbstman J., Speizer F.E., Camargo C.A. Validation of self-reported chronic obstructive pulmonary disease in a cohort study of nurses. Am J Epidemiol 2002, 155:965-971.
53. Rubin D.B. Inference and missing data. Biometrika 1976, 63:581-592.
54. Cuijpers P., Sijbrandij M., Koole S.L., et al. The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons. World Psychiatry: Official J World Psychiatr Assoc 2013, 12:137-148.
55. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
56. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979, 134:382-389.
57. Kessler R.C., Berglund P., Demler O., et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289:3095-3105.